Going after Huntington's disease again, ex-Teva R&D chief gets some cash for Prilenia's renewed efforts

Even while serving as the global R&D head for Teva several years ago, Michael Hayden had high hopes for a drug known as pridopidine. But …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Go­ing af­ter Hunt­ing­ton's dis­ease again, ex-Te­va R&D chief gets some cash for Prile­ni­a's re­newed ef­forts